IMM ImmuPharma plc

LSE · GB · Healthcare · Biotechnology · immupharma.co.uk

3.275GBp-0.76%Mkt Cap: 22.26M $P/E: —Today

ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the Unite…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap22.26M USD

Enterprise Value21.67M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-1.96M USD

Revenue/Share—

Last Price3.275 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees7

CountryGB

SectorHealthcare

IndustryBiotechnology

ISINGB0033711010

Valuation

P/E (Trailing)—

P/E (Forward)-0.01

PEG—

EV/EBITDA-8.23

EV/Revenue—

P/S—

P/B11.00

EPS (TTM)-0.01

EPS (Forward)-3.39

52W Range

3.0222% of range14.50

52W High14.50 GBp

52W Low3.022 GBp

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-263.18%

ROA-96.20%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.58M USD

CapEx (TTM)1.80K USD

FCF Margin—

FCF Yield-16.50%

Net Debt-756.34K USD

Net Debt/EBITDA0.29

Balance Sheet

Debt/Equity—

Current Ratio1.34

Quick Ratio0.78

Book Value/Sh0.0030 GBp

Cash/Share0.0010 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateDec 14, 2021

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.625.29M

Float606.17M

Insiders4.96%

Institutions16.29%

Technical

SMA 503.712 (-11.8%)

SMA 2004.955 (-33.9%)

Beta3.00

S&P 52W Chg14.58%

Avg Vol (30d)1.67M

Avg Vol (10d)1.46M

Technical Indicators

RSI (14)46.0

MACD-0.1140

MACD Signal-0.1007

MACD Hist.-0.0133

BB Upper4.084 GBp

BB Middle3.536 GBp

BB Lower2.987 GBp

BB Width31.03%

ATR (14)0.5919 GBp

Vol Ratio (20d)1.78x